Press release
Bi-Specific MAbS Market 2021 Analysis by Recent Developments and Trends- Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A or S, Bayer AG, Thermo Fisher Scientific, Inc.
Global Bi-Specific MAbS Market 2021 research report offers qualitative and quantitative insights in relation to industry growth rate, market segmentation, Bi-Specific MAbS market size, demand and revenue. The current Bi-Specific MAbS market trends that are expected to influence the future prospects of the industry are analyzed in the report. The report further investigates and assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.The global bi-specific MAbS market is expected to grow from $2.93 billion in 2020 to $3.75 billion in 2021 at a compound annual growth rate (CAGR) of 28%.
Inquire for Sample Copy of this Report:
https://www.marketinsightsreports.com/reports/08103166932/bi-specific-mabs-global-market-report-2021-covid-19-growth-and-change-to-2030-including-1-by-type-catumaxomab-removab-blinatumomab-duligotumab-sar-156597-2-by-product-type-in-vivo-in-vitro-3-by-indication-cancer-autoimmune-diseases-inflammatory-diseases-infectious-diseases-microbial-diseases-others-4-by-end-use-hospitals-research-institutes-other-covering-johnson-johnson-novartis-ag-hoffmann-la-roche-ltd-novo-nordisk-a-s-bayer-ag/inquiry?Mode=S48
The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Bi-Specific MAbS Market: Johnson & Johnson; Novartis AG; Hoffmann-La Roche Ltd.; Novo Nordisk A/S; Bayer AG; Thermo Fisher Scientific, Inc.; Bistro-Myers Squibb; Mylan N.V.; Daiichi Sankyo Company, Ltd.; Abbott; AstraZeneca; Eli Lilly; Merck & Co. Inc.; Amgen Inc.; Pfizer Inc.; GlaxoSmithKline plc; Roche; Sanofi; Genentech; Immunomedics; Chugai Pharmaceutical; EMD Serono; Emergent BioSolutions; Jounce Therapeutics; MarcoGenics; Merus; Neovii Biotech; NovImmune SA; OncoMed Pharmaceuticals; Pieris; Regeneron Pharmaceuticals and others.
Industry News and Updates:
In June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics.
In July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment.
Scope of this Report:
Markets Covered: 1) By Type: Catumaxomab (Removab); Blinatumomab; Duligotumab; SAR 156597
2) By Product Type: In Vivo; In Vitro
3) By Indication: Cancer; Autoimmune Diseases; Inflammatory Diseases; Infectious Diseases; Microbial Diseases; Others
4) By End Use: Hospitals; Research Institutes; Other
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Buy this Report:
https://www.marketinsightsreports.com/report/purchase/08103166932?mode=su?Mode=S48
Market Overview:
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $10 billion in 2025 at a CAGR of 28%.
The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.
Regional Analysis For Bi-Specific MAbS Market:
North America (The United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
Browse the Report Description And TOC:
https://www.marketinsightsreports.com/reports/08103166932/bi-specific-mabs-global-market-report-2021-covid-19-growth-and-change-to-2030-including-1-by-type-catumaxomab-removab-blinatumomab-duligotumab-sar-156597-2-by-product-type-in-vivo-in-vitro-3-by-indication-cancer-autoimmune-diseases-inflammatory-diseases-infectious-diseases-microbial-diseases-others-4-by-end-use-hospitals-research-institutes-other-covering-johnson-johnson-novartis-ag-hoffmann-la-roche-ltd-novo-nordisk-a-s-bayer-ag?Mode=S48
Important Features that are under Offering and Key Highlights of the Reports:
– Detailed overview of Market
– Changing market dynamics of the industry
– In-depth market segmentation by Type, Application etc.
– Historical, current and projected market size in terms of volume and value
– Recent industry trends and developments
– Competitive landscape of Market
– Strategies of key players and product offerings
– Potential and niche segments/regions exhibiting promising growth
The research includes historic data from 2015 to 2021 and forecasts until 2030 which makes the report an invaluable resource for industry executives, marketing, sales, and product managers, consultants, analysts, and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.
Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.
Please connect with our sales team (sales@marketinsightsreports.com ).
Contact Us:
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bi-Specific MAbS Market 2021 Analysis by Recent Developments and Trends- Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A or S, Bayer AG, Thermo Fisher Scientific, Inc. here
News-ID: 2481237 • Views: …
More Releases from Market Insights Reports
Cold Chain Monitoring Market May See a Big Move | BlueAir, Denso, Eureka Forbes, …
Market Insights Reports published a new research publication on "Cold Chain Monitoring Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Cold Chain Monitoring market was mainly driven by the increasing R&D spending across the world.
Some of the key players…
Outbound Logistics Market Next Big Thing | Major Giants- Draexlmaier, Faurecia, …
Market Insights Reports published a new research publication on "Outbound Logistics Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Outbound Logistics market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Veterinary Telemedicine Market May See a Big Move | Nestle, Deuerer, The J.M. Sm …
Market Insights Reports published a new research publication on "Veterinary Telemedicine Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Veterinary Telemedicine market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Precision Planting Market is Set to Fly High in Years to Come
Market Insights Reports published a new research publication on "Precision Planting Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Precision Planting market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
More Releases for MAbS
Rising Global Cancer Prevalence Fuels Anticancer Monoclonal Antibodies (MABS) Ma …
The Anti-Cancer MAbS Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Anti-Cancer MAbS Market Size and Projected Growth Rate?
The anti-cancer mAbs market size has grown rapidly in recent years. It will increase from $69.33 billion in 2024 to $76.92 billion in 2025…
Key Anti-Cancer MAbS Market Trend for 2025-2034: Product Innovations Drive Advan …
What Is the Future Outlook for the Anti-Cancer MAbS Market's Size and Growth Rate?
There has been a swift expansion in the size of the anti-cancer mabs market in the past few years. The market's growth is expected to jump from $69.33 billion in 2024 to $76.92 billion in 2025, maintaining a compound annual growth rate (CAGR) of 11.0%. Factors contributing to this growth during the historical period include a rise…
Anti-Cancer MAbS Market Size, Share, Statistics - 2033
The new report published by The Business Research Company, titled ""Anti-Cancer MAbS Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the anti-cancer mabs market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023…
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | Marketsand …
Monoclonal Antibody (mABs) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarkets™. The monoclonal antibody therapeutics market is primarily driven by factors such as increasing prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases. Technological advancements…
Monoclonal Antibody (mABs) Therapeutics Market worth $497.5 billion by 2029
Monoclonal Antibody (mABs) Therapeutics market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a latest report published by MarketsandMarkets Trademark
Monoclonal Antibody (mABs) Therapeutics Market [https://www.marketsandmarkets.com/Market-Reports/monoclonal-antibody-mabs-therapeutics-market-115323820.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach…
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM).
Download the sample report @ https://www.pharmaproff.com/request-sample/1117
Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.…
